{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Amentoflavone", "ERK", "NF-\u03baB", "apoptosis"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35478108", "DateCompleted": {"Year": "2022", "Month": "04", "Day": "29"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.21873/invivo.12812"], "Journal": {"ISSN": "1791-7549", "JournalIssue": {"Volume": "36", "Issue": "3", "PubDate": {"Year": "2022", "Season": "May-Jun"}}, "Title": "In vivo (Athens, Greece)", "ISOAbbreviation": "In Vivo"}, "ArticleTitle": "Reinforcement of Sorafenib Anti-osteosarcoma Effect by Amentoflavone Is Associated With the Induction of Apoptosis and Inactivation of ERK/NF-\u03baB.", "Pagination": {"StartPage": "1136", "EndPage": "1143", "MedlinePgn": "1136-1143"}, "Abstract": {"AbstractText": ["Sorafenib has been reported to show anti-osteosarcoma (anti-OS) efficacy by inhibiting metastasis; however, a phase II trial suggested that further combination with other agents could be necessary to achieve permanent remission. Herein, we aimed to identify whether amentoflavone, an abundant natural bioflavonoid found in many medicinal plants, can improve the treatment efficacy of sorafenib in OS.", "Cell viability, metastasis, apoptosis, and nuclear translocation of NF-\u03baB after amentoflavone combined with sorafenib were assayed by MTT, transwell migration/invasion, western blotting, flow cytometry, and immunofluorescence staining, respectively.", "The sorafenib-induced cytotoxicity and apoptosis of U-2 OS was enhanced by combining treatment with QNZ (NF-\u03baB inhibitor) or amentoflavone. NF-\u03baB nuclear translocation, NF-\u03baB phosphorylation, and metastasis capacity of U-2 OS cells were inhibited by amentoflavone combined with sorafenib.", "Amentoflavone may sensitize OS to sorafenib treatment by inducing intrinsic and extrinsic apoptosis and inhibiting ERK/NF-\u03baB signaling transduction."], "CopyrightInformation": "Copyright \u00a9 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Surgery, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C."}], "LastName": "Su", "ForeName": "Chun-Min", "Initials": "CM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Orthopedics, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C."}], "LastName": "Li", "ForeName": "Chi-Huan", "Initials": "CH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Imaging, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C."}], "LastName": "Huang", "ForeName": "Meng-Chu", "Initials": "MC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C."}, {"Identifier": [], "Affiliation": "Institute of Traditional Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, R.O.C."}], "LastName": "Yueh", "ForeName": "Po-Fu", "Initials": "PF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C."}], "LastName": "Hsu", "ForeName": "Fei-Ting", "Initials": "FT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Optometry, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C."}], "LastName": "Lin", "ForeName": "Rong-Fong", "Initials": "RF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicine, National Yang-Ming Chiao-Tung University Hospital, Yilan, Taiwan, R.O.C. hsulc@ymuh.ym.edu.tw."}], "LastName": "Hsu", "ForeName": "Li-Cho", "Initials": "LC"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Greece", "MedlineTA": "In Vivo", "NlmUniqueID": "8806809", "ISSNLinking": "0258-851X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biflavonoids"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-kappa B"}, {"RegistryNumber": "9I1VC79L77", "NameOfSubstance": "amentoflavone"}, {"RegistryNumber": "9ZOQ3TZI87", "NameOfSubstance": "Sorafenib"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Biflavonoids"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Bone Neoplasms"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "NF-kappa B"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Osteosarcoma"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Sorafenib"}], "CoiStatement": "The Authors declare no competing financial interests regarding this study."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Chang PY, Hsieh MJ, Hsieh YS, Chen PN, Yang JS, Lo FC, Yang SF, Lu KH. Tricetin inhibits human osteosarcoma cells metastasis by transcriptionally repressing MMP-9 via p38 and Akt pathways. Environ Toxicol. 2017;32(8):2032\u20132040. doi: 10.1002/tox.22380.", "ArticleIdList": ["10.1002/tox.22380", "27860196"]}, {"Citation": "Pan PJ, Tsai JJ, Liu YC. Amentoflavone inhibits metastatic potential through suppression of ERK/NF-\u0138B activation in osteosarcoma U2OS cells. Anticancer Res. 2017;37(9):4911\u20134918. doi: 10.21873/anticanres.11900.", "ArticleIdList": ["10.21873/anticanres.11900", "28870912"]}, {"Citation": "Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, Grieb P, Rutkowski P. Molecular biology of osteosarcoma. Cancers (Basel) 2020;12(8):2130. doi: 10.3390/cancers12082130.", "ArticleIdList": ["10.3390/cancers12082130", "PMC7463657", "32751922"]}, {"Citation": "Prudowsky ZD, Yustein JT. Recent insights into therapy resistance in osteosarcoma. Cancers (Basel) 2020;13(1):83. doi: 10.3390/cancers13010083.", "ArticleIdList": ["10.3390/cancers13010083", "PMC7795058", "33396725"]}, {"Citation": "Tian Z, Niu X, Yao W. Receptor tyrosine kinases in osteosarcoma treatment: which is the key target. Front Oncol. 2020;10:1642. doi: 10.3389/fonc.2020.01642.", "ArticleIdList": ["10.3389/fonc.2020.01642", "PMC7485562", "32984034"]}, {"Citation": "Kuo YC, Lin WC, Chiang IT, Chang YF, Chen CW, Su SH, Chen CL, Hwang JJ. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-\u0138B expression in vitro and in vivo. Biomed Pharmacother. 2012;66(1):12\u201320. doi: 10.1016/j.biopha.2011.09.011.", "ArticleIdList": ["10.1016/j.biopha.2011.09.011", "22265104"]}, {"Citation": "Shi T, Iwama H, Fujita K, Kobara H, Nishiyama N, Fujihara S, Goda Y, Yoneyama H, Morishita A, Tani J, Yamada M, Nakahara M, Takuma K, Masaki T. Evaluating the effect of lenvatinib on sorafenib-resistant hepatocellular carcinoma cells. Int J Mol Sci. 2021;22(23):13071. doi: 10.3390/ijms222313071.", "ArticleIdList": ["10.3390/ijms222313071", "PMC8657692", "34884875"]}, {"Citation": "Grignani G, Palmerini E, Dileo P, Asaftei SD, D\u2019Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508\u2013516. doi: 10.1093/annonc/mdr151.", "ArticleIdList": ["10.1093/annonc/mdr151", "21527590"]}, {"Citation": "Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009;278(2):145\u2013155. doi: 10.1016/j.canlet.2008.12.031.", "ArticleIdList": ["10.1016/j.canlet.2008.12.031", "19303700"]}, {"Citation": "Grignani G, Palmerini E, Ferraresi V, D\u2019Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M, Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98\u2013107. doi: 10.1016/S1470-2045(14)71136-2.", "ArticleIdList": ["10.1016/S1470-2045(14)71136-2", "25498219"]}, {"Citation": "Tobeiha M, Rajabi A, Raisi A, Mohajeri M, Yazdi SM, Davoodvandi A, Aslanbeigi F, Vaziri M, Hamblin MR, Mirzaei H. Potential of natural products in osteosarcoma treatment: Focus on molecular mechanisms. Biomed Pharmacother. 2021;144:112257. doi: 10.1016/j.biopha.2021.112257.", "ArticleIdList": ["10.1016/j.biopha.2021.112257", "34688081"]}, {"Citation": "Lin YC, Chen HY, Hsieh CP, Huang YF, Chang IL. Betulin inhibits mTOR and induces autophagy to promote apoptosis in human osteosarcoma cell lines. Environ Toxicol. 2020;35(8):879\u2013887. doi: 10.1002/tox.22924.", "ArticleIdList": ["10.1002/tox.22924", "32190974"]}, {"Citation": "Lee YJ, Chung JG, Chien YT, Lin SS, Hsu FT. Suppression of ERK/NF-\u0138B activation is associated with amentoflavone-inhibited osteosarcoma progression in vivo. Anticancer Res. 2019;39(7):3669\u20133675. doi: 10.21873/anticanres.13515.", "ArticleIdList": ["10.21873/anticanres.13515", "31262893"]}, {"Citation": "Tsai JJ, Hsu FT, Pan PJ, Chen CW, Kuo YC. Amentoflavone enhances the therapeutic efficacy of sorafenib by inhibiting anti-apoptotic potential and potentiating apoptosis in hepatocellular carcinoma in vivo. Anticancer Res. 2018;38(4):2119\u20132125. doi: 10.21873/anticanres.12452.", "ArticleIdList": ["10.21873/anticanres.12452", "29599330"]}, {"Citation": "Chen WL, Hsieh CL, Chen JH, Huang CS, Chen WT, Kuo YC, Chen CY, Hsu FT. Amentoflavone enhances sorafenib-induced apoptosis through extrinsic and intrinsic pathways in sorafenib-resistant hepatocellular carcinoma SK-Hep1 cells in vitro. Oncol Lett. 2017;14(3):3229\u20133234. doi: 10.3892/ol.2017.6540.", "ArticleIdList": ["10.3892/ol.2017.6540", "PMC5588078", "28927070"]}, {"Citation": "Wu CH, Hsu FT, Chao TL, Lee YH, Kuo YC. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-\u0138B axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo. Biomed Pharmacother. 2022;145:112437. doi: 10.1016/j.biopha.2021.112437.", "ArticleIdList": ["10.1016/j.biopha.2021.112437", "34864311"]}, {"Citation": "Yueh PF, Lee YH, Fu CY, Tung CB, Hsu FT, Lan KL. Magnolol induces the extrinsic/intrinsic apoptosis pathways and inhibits STAT3 signaling-mediated invasion of glioblastoma cells. Life (Basel) 2021;11(12):1399. doi: 10.3390/life11121399.", "ArticleIdList": ["10.3390/life11121399", "PMC8706091", "34947930"]}, {"Citation": "Yueh PF, Lee YH, Chiang IT, Chen WT, Lan KL, Chen CH, Hsu FT. Suppression of EGFR/PKC-\u03b4/NF-\u0138B signaling associated with imipramine-inhibited progression of non-small cell lung cancer. Front Oncol. 2021;11:735183. doi: 10.3389/fonc.2021.735183.", "ArticleIdList": ["10.3389/fonc.2021.735183", "PMC8576332", "34765548"]}, {"Citation": "Zhou J, Liu T, Wang W. Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: A meta-analysis of 16 studies. Medicine (Baltimore) 2018;97(44):e13051. doi: 10.1097/MD.0000000000013051.", "ArticleIdList": ["10.1097/MD.0000000000013051", "PMC6221749", "30383677"]}, {"Citation": "Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572\u2013577.", "ArticleIdList": ["10690541"]}, {"Citation": "Liao CL, Lin JH, Lien JC, Hsu SC, Chueh FS, Yu CC, Wu PP, Huang YP, Lin JG, Chung JG. The crude extract of Corni Fructus inhibits the migration and invasion of U-2 OS human osteosarcoma cells through the inhibition of matrix metalloproteinase-2/-9 by MAPK signaling. Environ Toxicol. 2015;30(1):53\u201363. doi: 10.1002/tox.21894.", "ArticleIdList": ["10.1002/tox.21894", "23955962"]}, {"Citation": "Assi T, Watson S, Samra B, Rassy E, Le Cesne A, Italiano A, Mir O. Targeting the VEGF pathway in osteosarcoma. Cells. 2021;10(5):1240. doi: 10.3390/cells10051240.", "ArticleIdList": ["10.3390/cells10051240", "PMC8157846", "34069999"]}, {"Citation": "Wu CH, Lin KH, Fu BS, Hsu FT, Tsai JJ, Weng MC, Pan PJ. Sorafenib induces apoptosis and inhibits NF-\u0138B-mediated anti-apoptotic and metastatic potential in osteosarcoma cells. Anticancer Res. 2021;41(3):1251\u20131259. doi: 10.21873/anticanres.14882.", "ArticleIdList": ["10.21873/anticanres.14882", "33788716"]}, {"Citation": "Marchandet L, Lallier M, Charrier C, Baud\u2019huin M, Ory B, Lamoureux F. Mechanisms of resistance to conventional therapies for osteosarcoma. Cancers (Basel) 2021;13(4):683. doi: 10.3390/cancers13040683.", "ArticleIdList": ["10.3390/cancers13040683", "PMC7915189", "33567616"]}, {"Citation": "Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra M. Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies. Cancers (Basel) 2021;13(12):2878. doi: 10.3390/cancers13122878.", "ArticleIdList": ["10.3390/cancers13122878", "PMC8228414", "34207685"]}, {"Citation": "Pfeffer CM, Singh ATK. Apoptosis: a target for anticancer therapy. Int J Mol Sci. 2018;19(2):448. doi: 10.3390/ijms19020448.", "ArticleIdList": ["10.3390/ijms19020448", "PMC5855670", "29393886"]}, {"Citation": "Zhang YP, Kong QH, Huang Y, Wang GL, Chang KJ. Inhibition of c-FLIP by RNAi enhances sensitivity of the human osteogenic sarcoma cell line U2OS to TRAIL-induced apoptosis. Asian Pac J Cancer Prev. 2015;16(6):2251\u20132256. doi: 10.7314/apjcp.2015.16.6.2251.", "ArticleIdList": ["10.7314/apjcp.2015.16.6.2251", "25824746"]}, {"Citation": "Liu XG, Xu J, Li F, Li MJ, Hu T. Down-regulation of miR-377 contributes to cisplatin resistance by targeting XIAP in osteosarcoma. Eur Rev Med Pharmacol Sci. 2018;22(5):1249\u20131257. doi: 10.26355/eurrev_201803_14465.", "ArticleIdList": ["10.26355/eurrev_201803_14465", "29565481"]}, {"Citation": "Godwin P, Baird AM, Heavey S, Barr MP, O\u2019Byrne KJ, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013;3:120. doi: 10.3389/fonc.2013.00120.", "ArticleIdList": ["10.3389/fonc.2013.00120", "PMC3655421", "23720710"]}, {"Citation": "Chen JH, Chen WL, Liu YC. Amentoflavone induces anti-angiogenic and anti-metastatic effects through suppression of NF-\u0138B activation in MCF-7 cells. Anticancer Res. 2015;35(12):6685\u20136693.", "ArticleIdList": ["26637885"]}, {"Citation": "Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, Yong BC, Zhang RH, Feng QS, Deng WG, Zhu XF, Zhou BP, Zeng YX, Shen JN, Kang T. Glycogen synthase kinase-3\u03b2, NF-\u0138B signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012;104(10):749\u2013763. doi: 10.1093/jnci/djs210.", "ArticleIdList": ["10.1093/jnci/djs210", "PMC3352834", "22534782"]}, {"Citation": "Tan B, Yuan Z, Zhang Q, Xiqiang X, Dong J. The NF-\u0138B pathway is critically implicated in the oncogenic phenotype of human osteosarcoma cells. J Appl Biomed. 2021;19(4):190\u2013201. doi: 10.32725/jab.2021.021.", "ArticleIdList": ["10.32725/jab.2021.021", "34907738"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "3", "Day": "12"}, {"Year": "2022", "Month": "4", "Day": "5"}, {"Year": "2022", "Month": "4", "Day": "6"}, {"Year": "2022", "Month": "4", "Day": "28", "Hour": "5", "Minute": "44"}, {"Year": "2022", "Month": "4", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "3"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35478108", "PMC9087062", "10.21873/invivo.12812", "36/3/1136"]}}], "PubmedBookArticle": []}